MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from issuance of
common stock from the...
$369,289K
Contributions from
non-controlling interests
$7,500K
Proceeds from exercise of
stock options
$3,217K
Net cash provided by
financing activities
$378,891K
Canceled cashflow
$1,115K
Net increase
(decrease) in cash, cash...
$38,569K
Canceled cashflow
$340,322K
Payments on finance lease
obligations
$1,115K
Proceeds from sales and
maturities of marketable...
$65,000K
Non-cash stock-based
compensation
$6,395K
Accounts payable
$3,754K
Depreciation and
amortization
$3,273K
Non-cash lease expense
$2,094K
Other assets
-$2,045K
Changes in fair value of
convertible preferred stock...
$363K
Net cash used in
investing activities
-$259,934K
Net cash used in
operating activities
-$80,388K
Canceled cashflow
$65,000K
Canceled cashflow
$17,924K
Purchase of marketable
securities
$321,153K
Net loss
-$61,714K
Accrued expenses and
other liabilities
-$21,049K
Purchases of property and
equipment
$3,781K
Deferred revenue
-$7,224K
Prepaid expenses and
other current assets
$6,221K
Operating lease
liabilities
-$1,841K
Amortization and accretion on
marketable securities
$146K
Other long term
liabilities
-$117K
Back
Back
Cash Flow
Generate Biomedicines, Inc. (GENB)
Generate Biomedicines, Inc. (GENB)
source: myfinsight.com